Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SERPASIL-APRESOLINE is a fixed-dose combination oral tablet approved in 1954 combining reserpine and hydralazine for antihypertensive therapy. The product represents a legacy small-molecule approach to blood pressure management. Mechanism of action involves sympathetic inhibition and vasodilation to reduce hypertension.
This legacy product faces imminent loss of exclusivity with minimal linked career opportunities, indicating a small, consolidating team focused on managed decline rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SERPASIL-APRESOLINE offers minimal career upside given zero linked job openings and LOE-approaching status. This is a managed-care, defensive position suitable for mid-career professionals managing portfolio wind-down rather than building growth experience.
Worked on SERPASIL-APRESOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.